BCL2 and B-cell chronic lymphocytic leukemia: To date, since elevated Bcl-2 expression has been reported in more than 90% of CLL patients, the use of Venetoclax has been extended to relapsed and refractory patients as monotherapy, or in combination with rituximab, obinutuzumab, or ibrutinib [104].